These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835 [TBL] [Abstract][Full Text] [Related]
3. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade. Okoye IS; Xu L; Walker J; Elahi S Cancer Immunol Immunother; 2020 Aug; 69(8):1423-1436. PubMed ID: 32246174 [TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
10. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related]
11. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267 [TBL] [Abstract][Full Text] [Related]
13. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Allard B; Pommey S; Smyth MJ; Stagg J Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257 [TBL] [Abstract][Full Text] [Related]
14. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 Wang K; Coutifaris P; Brocks D; Wang G; Azar T; Solis S; Nandi A; Anderson S; Han N; Manne S; Kiner E; Sachar C; Lucas M; George S; Yan PK; Kier MW; Laughlin AI; Kothari S; Giles J; Mathew D; Ghinnagow R; Alanio C; Flowers A; Xu W; Tenney DJ; Xu X; Amaravadi RK; Karakousis GC; Schuchter LM; Buggert M; Oldridge D; Minn AJ; Blank C; Weber JS; Mitchell TC; Farwell MD; Herati RS; Huang AC Cancer Cell; 2024 Sep; 42(9):1582-1597.e10. PubMed ID: 39214097 [TBL] [Abstract][Full Text] [Related]
15. Current and Emerging Perspectives on Immunotherapy for Melanoma. Daud A Semin Oncol; 2015 Dec; 42 Suppl 3():S3-S11. PubMed ID: 26598057 [TBL] [Abstract][Full Text] [Related]
16. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390 [TBL] [Abstract][Full Text] [Related]
17. Clinical Development of PD-1 in Advanced Melanoma. Munhoz RR; Postow MA Cancer J; 2018; 24(1):7-14. PubMed ID: 29360722 [TBL] [Abstract][Full Text] [Related]
18. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Chang KC; Burnham CA; Compton SM; Rasche DP; Mazuski RJ; McDonough JS; Unsinger J; Korman AJ; Green JM; Hotchkiss RS Crit Care; 2013 May; 17(3):R85. PubMed ID: 23663657 [TBL] [Abstract][Full Text] [Related]
19. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825 [TBL] [Abstract][Full Text] [Related]
20. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Chowell D; Morris LGT; Grigg CM; Weber JK; Samstein RM; Makarov V; Kuo F; Kendall SM; Requena D; Riaz N; Greenbaum B; Carroll J; Garon E; Hyman DM; Zehir A; Solit D; Berger M; Zhou R; Rizvi NA; Chan TA Science; 2018 Feb; 359(6375):582-587. PubMed ID: 29217585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]